FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
ABSTRACT Background FXYD3 is a Na/K‐ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo‐naive patients with surgically‐resected PDAC at a single centre (1993–2014). Method FXYD3 expressio...
Saved in:
Main Authors: | Nathalie B. Rasko, Christopher B. Nahm, John Turchini, Rachel Teh, Helge Rasmussen, Sooin Byeon, Sumit Sahni, Jaswinder S. Samra, Anthony J. Gill, Anubhav Mittal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.70500 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association between preoperative exercise tolerance and unplanned readmission in patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma: a retrospective analysis
by: Makoto Onji, et al.
Published: (2025-01-01) -
Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
by: Katarzyna Winter, et al.
Published: (2019-03-01) -
Microbiome in pancreatic cancer – What is new in 2024?
by: E. Hohmann, et al.
Published: (2024-10-01) -
Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma
by: Metoboroghene O. Mowoe, et al.
Published: (2025-01-01) -
Elevated SAMD3 expression in T cells predicts improved survival in pancreatic ductal adenocarcinoma patients
by: Lingyi Fu, et al.
Published: (2025-02-01)